ribociclib + binimetinib

Ribociclib + binimetinib is an investigational combination therapy consisting of ribociclib, a selective cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, and binimetinib, a selective mitogen-activated protein kinase kinase (MEK) inhibitor. This combination is designed to simultaneously inhibit the MAPK pathway and cell cycle progression, addressing frequent co-occurring dysregulation in NRAS-mutant melanoma. The regimen has shown clinical activity and a manageable safety profile in phase Ib/II trials for patients with NRAS-mutant melanoma, with enhanced efficacy among patients with concurrent cell cycle gene alterations. Common adverse events include creatine phosphokinase elevation, rash, edema, anemia, nausea, diarrhea, and fatigue[1][2][3].